低分子肝素治疗慢性肺源性心脏病临床观察

The Clinical Effect of Low-molecular-weight Heparins Calcium on Chronic Pulmonary Heart Disease

目的观察低分子肝素(LMWHC)治疗慢性肺源性心脏病(慢性肺心病)的临床疗效。方法选择我院80例慢性肺心病患者,随机分为治疗组40例和对照组40例,两组患者均给予氧疗,抗感染、止咳,祛痰、平喘、扩管、利尿、强心等治疗,治疗组患者在此基础上加用LMWHC,6150U,皮下注射,2次/d,应用21d。观察两组患者治疗后血流动力学、凝血指标和心肺功能改变。结果两组患者治疗后心功能、全血黏度、血小板黏附率、ESR、Fbg、APTT、FEV1间差异均有显著性意义(P<0·05)。治疗期间未出现严重的出血性并发症。结论在综合治疗慢性肺心病中,配伍使用LMWHC治疗,可改善心肺功能。

Objective TO observe the clinical effect that the patients with Chronic pulmonary Heart disease （CPHD） were treated by the low - molecular - weigh beparins calcium （LMWHC）. Methods With randomly and signal blind way, the control patients were therapied with LMWHC addedly, which based on the routed treat ways. Their changes, hemodynamics, hemorheology, heart and pulmonary function, were observed. Results The heart and pulmonary function of the control were better than the contrast＇s. The plasma viscosity were deceased in the control group, but their PLT were no difference （ P 〉 0. 05）. During the treatment, no serious side effects were occurred. Conclusion Added the LMWHF in treating CPHD would improve the heart and pulmonary function, and clinical effect.